Nucleotide variations in genes encoding plasminogen activator inhibitor-2 and serine proteinase inhibitor B10 associated with prostate cancer

Journal of Human Genetics

Volumn 50, Issue 10, 2005, Pages 507-515

  Shioji, Go ^a   Ezura, Yoichi ^a,b   Nakajima, Toshiaki ^a   Ohgaki, Kenji ^a   Fujiwara, Hiromichi ^a   Kubota, Yoshinobu ^c   Ichikawa, Tomohiko ^d   Inoue, Katsuki ^e   Shuin, Taro ^f   Habuchi, Tomonori ^g   Ogawa, Osamu ^h   Nishimura, Taiji ^a   Emi, Mitsuru ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^c YOKOHAMA CITY UNIVERSITY   (Japan)

^d CHIBA UNIVERSITY   (Japan)

^e SHOWA UNIVERSITY FUJIGAOKA HOSPITAL   (Japan)

^f KOCHI MEDICAL SCHOOL   (Japan)

^g AKITA UNIVERSITY   (Japan)

^h KYOTO UNIVERSITY   (Japan)

Author keywords

Linkage disequilibrium; Missense polymorphism; PAI2; Serine proteinase family; SERPINB10

Indexed keywords

NUCLEOTIDE; PLASMINOGEN ACTIVATOR INHIBITOR 2; SERINE PROTEINASE INHIBITOR;

ADULT; ALLELE; ARTICLE; CANCER PATIENT; CANCER RISK; CARCINOGENESIS; CASE CONTROL STUDY; CLINICAL EXAMINATION; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA POLYMORPHISM; GENE LINKAGE DISEQUILIBRIUM; GENE LOCUS; GENE REPLICATION; GENETIC CODE; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE DETECTION; HIGH RISK POPULATION; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; PROSTATE CANCER;

ALLELES; CASE-CONTROL STUDIES; CHROMOSOMES, HUMAN, PAIR 18; HUMANS; LINKAGE DISEQUILIBRIUM; MALE; MUTATION, MISSENSE; PLASMINOGEN ACTIVATOR INHIBITOR 2; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC NEOPLASMS; QUANTITATIVE TRAIT LOCI; RISK FACTORS; SERPINS;

EID: 27644528117     PISSN: 14345161     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10038-005-0285-1     Document Type: Article

References (22)

1. Berthon P, Valeri A, Cohen-Akenine A, Drelon E, Paiss T, Wohr G, Latil A, Millasseau P, Mellah I, Cohen N, Blanche H, Bellane-Chantelot C, Demenais F, Teillac P, Le Duc A, de Petriconi R, Hautmann R, Chumakov I, Bachner L, Maitland NJ, Lidereau R, Vogel W, Fournier G, Mangin P, Cussenot O et al. (1998) Predisposing gene for early-onset prostate cancer, localized on chromosome 1q42.2-43. Am J Hum Genet 62:1416-1424
2. Carpten J, Nupponen N, Isaacs S, Sood R, Robbins C, Xu J, Faruque M, Moses T, Ewing C, Gillanders E, Hu P, Bujnovszky P, Makalowska I, Baffoe-Bonnie A, Faith D, Smith J, Stephan D, Wiley K, Brownstein M, Gildea D, Kelly B, Jenkins R, Hostetter G, Matikainen M, Schleutker J, Klinger K, Connors T, Xiang Y, Wang Z, De Marzo A, Papadopoulos N, Kallioniemi OP, Burk R, Meyers D, Gronberg H, Meltzer P, Silverman R, Bailey-Wilson J, Walsh P, Isaacs W, Trent J (2002) Germline mutations in the ribonuclease L gene in families showing linkage with HPC1. Nat Genet 30:181-184
3. Carter BS, Beaty TH, Steinberg GD, Childs B, Walsh PC (1992) Mendelian inheritance of familial prostate cancer. Proc Natl Acad Sci USA 89:3367-3371
4. Gibbs M, Stanford JL, McIndoe RA, Jarvic GP, Kolb S, Goode EL, Chakrabarti L, Schster EF, Buckley VA, Miller EL, Brandzel S, Li S, Hood L, Ostrander EA (1999) Evidence for a rare prostate cancer-susceptibility locus at chromosome 1p36. Am J Hum Genet 64:776-787
5. Haga H, Yamada R, Ohnishi Y, Nakamura Y, Tanaka T (2002) Gene-based SNP discovery as part of the Japanese Millennium Genome Project: identification of 190,562 genetic variations in the human genome. J Hum Genet 47:80-87
6. Hsing AW, Chen C, Chokkalingam AP, Gao YT, Dightman DA, Nguyen HT, Deng J, Cheng J, Sesterhenn IA, Mostofi FK, Stanczyk FZ, Reichardt JK (2001) Polymorphic markers in the SRD5A2 gene and prostate cancer risk: a population-based case-control study. Cancer Epidemiol Biomarkers Prev 10:1077-1082
7. Iida A, Saito S, Sekine A, Mishima C, Kitamura Y, Kondo K, Harigae S, Osawa S, Nakamura Y (2002) Catalog of 77 single-nucleotide polymorphism (SNPs) in the carbohydrate sulfotransferase 1 (CHST1) and carbohydrate sulfotransferase 3 (CHST3) genes. J Hum Genet 47:14-19
8. Irvine RA, Yu MC, Ross RK, Coetzee GA (1995) The CAG and GGC microsatellites of the androgen receptor gene are in linkage disequilibrium in men with prostate cancer. Cancer Res 55:1937-1940
9. Iwasaki H, Emi M, Ezura Y, Ishida R, Kajita M, Kodaira M, Yoshida H, Suzuki T, Hosoi T, Inoue S, Shiraki M, Swensen J, Orimo H (2003) Association of a Trp16Ser variation in the gonadotropin releasing hormone signal peptide with bone mineral density, revealed by SNP-dependent PCR typing. Bone 32:185-190
10. Kruithof EK, Baker MS, Bunn CL (1995) Biological and clinical aspects of plasminogen activator inhibitor type 2. Blood 86:4007-4024
11. Kumar S, Baglioni C (1991) Protection from tumor necrosis factor-mediated cytolysis by overexpression of plasminogen activator inhibitor type-2. J Biol Chem 266:20960-20964
12. Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M, Pukkala E, Skytthe A, Hemminki K (2000) Environmental and heritable factors in the causation of cancer-analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 13:78-85
13. Livak KJ (1999) Allelic discrimination using fluorogenic probes and the 5′ nuclease assay. Genet Anal 14:143-149
14. Miller PT, Sarçñina IB, Saccone NL, Putzel J, Laitinen T, Cao A, Kere J, Pilia G, Rice JP, Kwok PY (2000) Juxtaposed regions of extensive minimal linkage disequilibrium in human Xq25 and Xq28. Nat Genet 25:324-328
15. Ng PC, Henikoff S (2001) Predicting deleterious amino acid substitutions. Genome Res 11:863-874
16. Ohnishi Y, Tanaka T, Ozaki K, Yamada R, Suzuki H, Nakamura Y (2001) A high-throughput SNP typing system for genome-wide association studies. J Hum Genet 46:471-477
17. Ostrander EA, Stanford JL (2000) Genetics of prostate cancer: too many loci, too few genes. Am J Hum Genet 67:1367-1375
18. Silverman GA, Bird PI, Carrell RW, Church FC, Coughlin PB, Gettins PG, Irving JA, Lomas DA, Luke CJ, Moyer RW, Pemberton PA, Remold-O'Donnell E, Salvesen GS, Travis J, Whisstock JC (2001) The serpins are an expanding superfamily of structurally similar but functionally diverse proteins. Evolution, mechanism of inhibition, novel functions, and a revised nomenclature. J Biol Chem 276:33293-33296
19. Smith JR, Freije D, Carpten JD, Gronberg H, Xu J, Isaacs SD, Brownstein MJ, Bova GS, Guo H, Bujnovszky P, Nusskern DR, Damber JE, Bergh A, Emanuelsson M, Kallioniemi OP, Wish PC, Collins FS, Trent JM, Isaacs WB (1996) Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science 274:1371-1374
20. Tavtigian SV, Simard J, Teng DH, Abtin V, Baumgard M, Beck A, Camp NJ, Carillo AR, Chen Y, Dayananth P, Desrochers M, Dumont M, Farnham JM, Frank D, Frye C, Ghaffari S, Gupte JS, Hu R, Iliev D, Janecki T, Kort EN, Laity KE, Leavitt A, Leblanc G, McArthur-Morrison J, Pederson A, Penn B, Peterson KT, Reid JE, Richards S, Schroeder M, Smith R, Snyder SC, Swedlund B, Swensen J, Thomas A, Tranchant M, Woodland AM, Labrie F, Skolnick MH, Neuhausen S, Rommens J, Cannon-Albright LA (2001) A candidate prostate cancer susceptibility gene at chromosome 17p. Nat Genet 27:172-180
21. Wang WY, Barratt BJ, Clayton DG, Todd JA (2005) Genome-wide association studies: theoretical and practical concerns. Nat Rev Genet 6:109-118
22. Xu J, Meyers D, Freije D, Isaacs S, Wiley K, Nusskern D, Ewing C, Wilkens E, Bujnovszky P, Bova GS, Walsh P, Isaacs W, Schleutker J, Matikainen M, Tammela T, Visakorpi T, Kallioniemi OP, Berry R, Schaid D, French A, McDonnell S, Schroeder J, Blute M, Thibodeau S, Trent J et al. (1998) Evidence for a prostate cancer susceptibility locus on the X chromosome. Nat Genet 20:175-179